Bicycle Therapeutics Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Bicycle Therapeutics de 3.2% y 50.2% por año respectivamente. Se prevé que el BPA crezca en un 11.1% al año. Se espera que la rentabilidad financiera sea de -157.1% en 3 años.
Información clave
3.2%
Tasa de crecimiento de los beneficios
11.1%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 23.5% |
| Tasa de crecimiento de los ingresos | 50.2% |
| Rentabilidad financiera futura | -157.1% |
| Cobertura de analistas | Good |
| Última actualización | 09 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19
Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates
Mar 08Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Feb 23Announcing: Bicycle Therapeutics (NASDAQ:BCYC) Stock Increased An Energizing 141% In The Last Year
Jan 19Bicycle Therapeutics gives out pipeline update, shares rise
Jan 14What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?
Dec 15Bicycle Therapeutics settles IP dispute with Pepscan
Nov 30Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 48 | -290 | -263 | -182 | 9 |
| 12/31/2025 | 28 | -265 | -255 | -169 | 11 |
| 12/31/2024 | 28 | -228 | -211 | -173 | 13 |
| 12/31/2023 | 27 | -181 | -64 | -61 | N/A |
| 9/30/2023 | 25 | -162 | -48 | -44 | N/A |
| 6/30/2023 | 23 | -140 | -55 | -48 | N/A |
| 3/31/2023 | 15 | -124 | -122 | -106 | N/A |
| 12/31/2022 | 14 | -113 | -105 | -86 | N/A |
| 9/30/2022 | 15 | -101 | -85 | -66 | N/A |
| 6/30/2022 | 16 | -87 | -54 | -39 | N/A |
| 3/31/2022 | 14 | -78 | -34 | -27 | N/A |
| 12/31/2021 | 12 | -67 | -17 | -15 | N/A |
| 9/30/2021 | 12 | -66 | -22 | -21 | N/A |
| 6/30/2021 | 11 | -62 | -54 | -53 | N/A |
| 3/31/2021 | 11 | -56 | -54 | -53 | N/A |
| 12/31/2020 | 10 | -51 | -19 | -18 | N/A |
| 9/30/2020 | 12 | -38 | -7 | -6 | N/A |
| 6/30/2020 | 9 | -37 | -8 | -7 | N/A |
| 3/31/2020 | 9 | -35 | -4 | -2 | N/A |
| 12/31/2019 | 14 | -31 | -30 | -29 | N/A |
| 9/30/2019 | 10 | -33 | -34 | -33 | N/A |
| 6/30/2019 | 11 | -31 | -28 | -26 | N/A |
| 3/31/2019 | 11 | -26 | -25 | -24 | N/A |
| 12/31/2018 | 7 | -22 | -27 | -26 | N/A |
| 9/30/2018 | 7 | -21 | -20 | -19 | N/A |
| 12/31/2017 | 2 | -16 | -3 | -1 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que BCYC siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que BCYC siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que BCYC siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (50.2% al año) de BCYC crezcan más rápidamente que los del mercado US (8.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (50.2% al año) de BCYC crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: BCYC se prevé que no sea rentable en 3 años.